Bellevue Life Sciences Acquisition Corp. (BLAC)
| Market Cap | 95.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 75,043 |
| Shares Out | 9.06M |
| EPS (ttm) | 0.01 |
| PE Ratio | 1,050.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 153 |
| Open | 10.50 |
| Previous Close | 10.47 |
| Day's Range | 10.50 - 10.50 |
| 52-Week Range | 10.09 - 11.16 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BLAC
Bellevue Life Sciences Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company intends to acquire companies in the healthcare industry. Bellevue Life Sciences Acquisition Corp. was founded in 2020 and is based in Bellevue, Washington. Bellevue Life Sciences Acquisition Corp. operates as a subsidiary of Bellevue Global Life Sciences Investors LLC. [Read more]
Financial Performance
Financial StatementsNews
OSR Holdings Co., Ltd. Enters Into Business Combination Agreement with Bellevue Life Sciences Acquisition Corp.
BELLEVUE, Wash. and SEOUL, South Korea , Nov. 16, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC), a publicly traded special purpose acquisition company ("BLAC"), and OSR ...
Bellevue Life Sciences Acquisition Corp. and OSR Holdings Sign an Exclusive Letter of Intent for a Business Combination
BELLEVUE, Wash. and SEOUL, South Korea, July 11, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (Nasdaq: BLAC), a publicly traded special purpose acquisition company ("BLAC"), and OSR H...
Bellevue Life Sciences Acquisition Corp. Announces Closing of Full Over-allotment Option
BELLEVUE, Wash. , Feb. 21, 2023 /PRNewswire/ -- Bellevue Life Sciences Acquisition Corp. (the "Company" or "we") today announced the closing of the over-allotment option that the Company granted to th...
Bellevue Life Sciences Acquisition Corp. Announces Closing of $60 Million Initial Public Offering
Bellevue Life Sciences Acquisition Corp. (NASDAQ: BLACU), a newly organized blank check company incorporated in Delaware...
Bellevue Life Sciences Acquisition Corp. Announces Pricing of $60 Million Initial Public Offering
Bellevue Life Sciences Acquisition Corp. today announced the pricing of its initial public offering of 6,000,000 units at a price of $10.00 per unit.
Biotech SPAC Bellevue Life Sciences Acquisition files for a $60 million IPO
Bellevue Life Sciences Acquisition, a blank check company backed by Bellevue Capital Management targeting the biotech sector, filed on Friday with the SEC to raise up to $60 million in an initial publ...
Bellevue Life Sciences Acquisition IPO Registration Document (S-1)
Bellevue Life Sciences Acquisition has filed to go public with an IPO on the NASDAQ.